Galecto

Galecto EV/EBIT

Delisted·Sep 22, 2026

The EV/EBIT (Enterprise Value to EBIT) of Galecto (GLTO) as of Oct 26, 2026 is -8.02. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -75.95 — a change of -89.44% (higher).

EV/EBIT

-8.02

YoY

-89.44%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Galecto is 2025 -8.02 . EV/EBIT (Enterprise Value to EBIT) of Galecto was 2024 -75.95 . It decreases by -89.44% higher compared to the previous year.

The Galecto EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-131.00 USD
Jan 1, 2019
-43.38 USD
Jan 1, 2020
-50.26 USD
Jan 1, 2021
-32.37 USD
Jan 1, 2022
-27.62 USD
Jan 1, 2023
-42.37 USD
Jan 1, 2024
-75.95 USD
Jan 1, 2025
-8.02 USD
The Galecto EV/EBIT history
YEAREV/EBITYoY
-8.02-89.44%
-75.95+79.27%
-42.37+53.38%
-27.62-14.67%
-32.37-35.59%
-50.26+15.86%
-43.38-66.88%
-131.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Galecto Stock analysis

What does Galecto do? Galecto, Inc. develops small molecule therapeutics targeting galectin-3 and LOXL2 for cancer and fibrotic diseases. The company focuses on GB0139 for Idiopathic Pulmonary Fibrosis (IPF), GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. These products are designed to address biological processes central to these conditions. The firm targets medical professionals and healthcare institutions seeking novel treatments for fibrotic and oncological disorders. Galecto's revenue streams come from the development and potential future commercialization of its therapeutic candidates. The company is a clinical-stage biotechnology firm, meaning it is currently in the development phase and has not yet generated revenue from product sales. The primary buyers of Galecto's products will be healthcare providers and pharmaceutical distributors once the drugs are approved and marketed. The company's product pipeline includes GB0139 for IPF, GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. These products are developed as small molecule inhibitors targeting specific biological processes. Galecto's focus on clinical-stage development indicates that it is still in the research and testing phase, with no current revenue from product sales. Galecto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Galecto stock

EV/EBIT (Enterprise Value to EBIT) of Galecto is -8.02 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Galecto changed from -75.95 to -8.02, representing a -89.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Galecto since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Galecto with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Galecto

All Key Metrics — Galecto